High-Definition MALDI MS Imaging: Full Integration of the Ion Mobility Dimension from Acquisition to Visualization

The last few years have seen a rapid increase in the interest in mass spectral imaging directly from tissue. Mass spectrometry (MS) is an attractive proposition for imaging, as a large range of different compounds can be detected simultaneously; it is relatively inexpensive compared with many other imaging techniques and does not require labeling of compounds of interest.

A major limitation of MALDI (Matrix-assisted laser desorption/ionization) MS imaging using conventional MALDI-TOF and TOF-TOF analyzers, which separate by m/z, is the absence of any additional dimension of separation. Owing to the complexity of the samples under investigation, this poses a major risk of isobaric ions distorting the ion distribution and, thus, invalidating results. With the introduction of the Waters MALDI SYNAPT HDMS system, it is possible to separate ions using ion mobility separation (IMS) prior to mass analysis. IMS allows for the separation of ions according to their size, shape and charge state. Using this technique it is possible to separate different compound classes, giving additional confidence that the true distribution of an ion of interest is observed.

We presented the key advantages that MALDI SYNAPT platforms offer, especially for the MALDI imaging application. The webinar also introduced the new Waters proprietary High Definition Imaging (HDI) 1.0 MALDI software, which was designed to simplify and streamline the imaging workflow, and fully incorporate the benefits of ion mobility separation into the downstream data analysis scheme.

Topics covered:

• Waters HDI 1.0 MALDI software
• Advantages of using ion mobility separation for untargeted MALDI imaging analysis
• A novel method of acquisition, where precursor and fragment information is recorded within one single experiment

Who attended:

• Academic researchers looking at biomarkers discovery
• Discovery and early-development laboratory scientists investigating drug distribution

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelist.

Panelist

Emmanuelle Claude
Principal Scientist, Pharmaceutical & Life Sciences Discovery
Waters Corporation, Manchester, UK

More webinars in this series

Exact Mass MSE: An Attractive Option For Quantification in Discovery DMPK

Opportunities for ensuring compliance and managing change: A next-generation platform strategy for regulated pharmaceutical laboratories

Xevo TQ-S: Breaking Industry Barriers

Bioanalysis of Therapeutic and Endogenous Peptides: Understanding and Overcoming the Challenges of Working with Large Molecules

Resolving the Complexity of Proteomic Samples with Ion Mobility-Mass Spectrometry